Efficacy

Efficacy of Portrazza (necitumumab) in Lung Cancer

Portrazza (necitumumab) is a monoclonal antibody designed for the treatment of lung cancer, specifically for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for metastatic disease. Necitumumab targets the epidermal growth factor receptor (EGFR), a protein found on the surface of many cancer cells. By binding to EGFR, necitumumab can block the signals that promote the growth of cancer cells.

The efficacy of Portrazza was established in a clinical trial that compared necitumumab plus chemotherapy (gemcitabine and cisplatin) to chemotherapy alone. The study showed a statistically significant improvement in overall survival for patients receiving necitumumab in combination with chemotherapy compared to those who received chemotherapy alone. However, it is important to note that the benefit was modest and that necitumumab is associated with some serious risks, which should be weighed against the potential benefit.

Efficacy of Enhertu (fam-trastuzumab deruxtecan-nxki) in Lung Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is a targeted therapy used in the treatment of lung cancer, specifically for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 mutation and who have received a prior systemic therapy. This medication is a conjugate of an anti-HER2 antibody and a cytotoxic agent, which allows for the delivery of the chemotherapy directly to the cancer cells that overexpress HER2.

The efficacy of Enhertu in lung cancer was demonstrated in a multicenter, open-label, single-arm trial, where patients with HER2-mutant NSCLC who had received prior systemic therapy were treated with Enhertu. The results showed a significant response rate with a median duration of response that was clinically meaningful. These findings suggest that Enhertu is an effective treatment option for patients with HER2-mutant NSCLC who have limited treatment options due to the progression of disease after other therapies.